For Industry

Patient-Focused Drug Development: Disease Area Meetings Held in Fiscal Years 2013-2017

From 2012 to 2017, under the fifth authorization of PDUFA (PDUFA V), FDA conducted 24 disease-specific patient-focused drug development (PFDD) meetings to more systematically obtain the patient perspective on specific diseases and their treatments. PFDD meetings provide key stakeholders, including FDA, patient advocates, researchers, drug developers, healthcare providers, and others, an opportunity to hear the patient’s voice.

The list of 24 disease-area PFDD meetings conducted under PDUFA V can be found below, along with links to individual meeting webpages where all meeting materials, including transcripts, webcast recordings and presentation slides are publicly available. Following each PFDD meeting, FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report.

More information on the selection of disease areas for fiscal years 2013-2015 can be found in the Federal Register Notice (PDF - 111KB) published on April 11, 2013. More information on the selection of disease areas for fiscal years 2016-2017 can be found in the Federal Register Notice published on July 2, 2015.

Meetings Held in FY 2016 – 2017

2013-2015 Meetings are in the FDA Archive

 

Page Last Updated: 03/23/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English